Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011

VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes Association (ADA) meeting to be held June 24th to June 28th, 2011, at the San Diego Convention Center, San Diego, CA.  Timothy Garvey, MD, Professor of Medicine and Chair of the Department of Nutrition Sciences at UAB, will present his findings on the impact of QNEXA treatment on metabolic syndrome.  Donna Ryan, MD, Associate Executive Director for Clinical Research at Pennington Biomedical Research Center, will present her findings on the prevention of diabetes and normalization of fasting glucose in prediabetics after two years of QNEXA treatment.  Lastly, Robert Kushner, MD, Clinical Director at Northwestern University Comprehensive Center on Obesity (NCCO), will share his analysis of long-term weight loss with QNEXA and the resulting improvement in glycemic biomarkers.  

Top-line results from the SEQUEL study have been previously presented but the ADA presentations represent the first detailed presentation of glycemic data to ADA members.  Details on the presentation times are as follows:

Sunday, June 26, 2011 – General Poster Session II, Abstract # 1875-P, Presentation time 12:00-14:00 (local time)

Monday, June 27, 2011 – Pharmacologic Treatment of Obesity, Abstract # 1875-P, Guided Audio Tour, Presentation time 13:00-14:00 (local time)

Authors:  W. Timothy Garvey, MD; Robert R. Henry, MD; Craig A. Peterson MS; Charles H. Bowden, MD

Title:  WEIGHT LOSS WITH CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) REVERSES METABOLIC SYNDROME (METS) AND IMPROVES ASSOCIATED TRAITS

Sunday, June 26, 2011 – General Poster Session II, Abstract # 1887-P, Presentation time 12:00-14:00 (local time)

Authors:  Donna H. Ryan, MD; W. Timothy Garvey, MD; Barbara Troupin, MD, MBA; Wesley Day, PhD

Title:  DIABETES PREVENTION AND NORMALIZATION OF FASTING GLUCOSE IN SUBJECTS WITH PREDIABETES USING CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) IN A 2 YEAR WEIGHT LOSS INTERVENTION

Sunday, June 26, 2011 – General Poster Session II, Abstract # 1906-P, Presentation time 12:00-14:00 (local time)

Authors:  Robert F. Kushner, MD; W. Timothy Garvey, MD; Barbara Troupin, MD, MBA; Wesley Day, PhD

Title:  LONG-TERM WEIGHT LOSS AND IMPROVEMENT IN GLYCEMIC PARAMETERS WITH LOW-DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR)

All posters will be displayed in Hall B – Poster Hall, General Poster Session II on Sunday, June 26th between 12:00-14:00 (local time). In addition, the poster titled, "Weight Loss with Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Reverses Metabolic Syndrome (MetS) and Improves Associated Traits" will be featured in a Guided Audio Tour on Monday, June 27th between 13:00-14:00 (Hall B – Poster Hall).

Source:

VIVUS, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Intense, regular walking may help prevent Type 2 diabetes among 70 and 80 year olds